David Cana

David Cana serves as Co-CEO & Chief People & Investment Officer at mesoestetic Pharma Group. mesoestetic Pharma Group operates in the pharmaceuticals sector with approximately 380.0 employees. The company is headquartered in Barcelona, Catalonia. mesoestetic Pharma Group generates annual revenue of 66000000.0.

Industry & Role Insights

• • MessageCEO tracks 1,288 executives in the pharmaceuticals sector.
• • 1,458 executive contacts are available in Catalonia.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS Mailchimp Mandrill Outlook Microsoft Office 365 CloudFlare Hosting Sendgrid Zendesk Magento 2 Community Adobe Marketing Cloud OneTrust Drupal VueJS Atlassian Cloud Salesforce Google Analytics Google translate API DoubleClick Conversion Google AdWords Conversion Google Maps (Non Paid Users) Mobile Friendly Google Places Affiliate Window reCAPTCHA Google Maps Paypal Bing Ads Vimeo Facebook Widget WordPress.org Stripe Bootstrap Framework YouTube DoubleClick Google Dynamic Remarketing Google Font API Hotjar Facebook Login (Connect) New Relic Facebook Custom Audiences Google Tag Manager Google AdSense Cedexis Radar Adobe Media Optimizer Android

cosmetica medicina estetica salud ginecoestetica pharma farmacia industria farmaceutica antiedad antiaging fillers acido hialuronico despigmentacion pharmaceutical manufacturing anti-aging skin care facial treatments moisturizers pigment control professional treatments cleansing solutions hair care sensitive skin solutions exfoliation anti-wrinkle skin hydration photo-protection dermal fillers retinol products serums nutritional supplements acne solutions depigmentation skin rejuvenation skin balance hydrating masks anti-fatigue solutions peels tranexamic acid hyaluronic acid cosmetic procedures facial rejuvenation cleansing foams skin revitalization glycolic acid skin brightening collagen boosters anti-blemish exosome therapy beauty club professional skincare trichology treatments home care solutions lip care anti-cellulite restorative skincare scientific efficacy dermatological products skin repair beauty academy natural extracts hyaluronic boosters stress relief products pharmaceutical laboratory dermatology aesthetic medicine skincare solutions anti-aging treatments cosmeceuticals nutraceuticals medical devices injectable treatments scientific research innovation quality assurance global presence beauty industry skin health acne treatment body remodeling sun protection clinical-grade products aesthetic practitioners medical professionals consumer skincare luxury skincare effective solutions safety standards r&d investment hyperpigmentation treatment skincare products professional use home care products international markets customer satisfaction advanced skincare solutions pharmaceuticals medical hospital & health care

YM

Yathendra Madineni Chief Executive Officer at 4C Pharma Solutions

RB

Ronan Brown Chief Operating Officer at 4G Clinical

HK

Hitoshi Kamiya Chief Executive Officer at A2 Healthcare Corporation

LJ

Lars Jensen CEO at A-apoteket

TL

Tien Lee CEO at Aardvark Therapeutics, Inc.

How can I contact David Cana?

David Cana's verified email address is available on MessageCEO. They currently work at mesoestetic Pharma Group. Pro subscribers can access direct email addresses for over 200,000 executives.

What company does David Cana lead?

David Cana is Co-CEO & Chief People & Investment Officer at mesoestetic Pharma Group, a company in the pharmaceuticals sector with 380.0 employees. The company is based in Barcelona, Catalonia.

What industry is David Cana in?

David Cana works in the pharmaceuticals industry as Co-CEO & Chief People & Investment Officer at mesoestetic Pharma Group. MessageCEO provides verified contact information for executives across all major industries.

Is David Cana's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. David Cana's profile is kept up-to-date with the latest available information.

Last updated: April 7, 2026